Safety profile of faricimab: a multi-source pharmacovigilance analysis using FAERS and JADER
This study identified previously unreported safety signals, suggesting the need for potential updates to faricimab's safety labeling. Faricimab's dual-target mechanism presents unique safety concerns. Clinicians should monitor ocular inflammation and vascular complications, particularly in younger males and Asian patients. Further studies using real-world data are needed to validate these findings.
Authors
- Zhou Fang (ORCID: https://orcid.org/0000-0001-7021-1725)
- Shangze Li (ORCID: https://orcid.org/0000-0003-3134-532X)
- Yu Gao (ORCID: https://orcid.org/0000-0001-7845-801X)
- Yuan Zhang (ORCID: https://orcid.org/0000-0001-9284-9404)
- Ziyi Wang (ORCID: https://orcid.org/0009-0000-0729-4740)
- Zhifu Li (ORCID: https://orcid.org/0000-0001-5702-5928)
- Chunran Liu (ORCID: https://orcid.org/0000-0002-1802-6917)
Institutions
- Second Military Medical University (CN)
- Changhai Hospital (CN)
- Changzhou No.2 People's Hospital (CN)
Publication Details
- Journal
- BMC Pharmacology and Toxicology
- Published
- 2025-04-12
- DOI
- https://doi.org/10.1186/s40360-025-00902-6
- Citations
- 6
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- article
- Field-Weighted Citation Impact
- 7.84